259 related articles for article (PubMed ID: 22227516)
1. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
2. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
3. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Parambil JG; Woodard TD; Koc ON
Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
7. [Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report].
Mozdon MA; Ponomarev RV; Tsvetaeva NV; Shabrin AV; Ermachenkova EI; Larichev SE; Lukina EA
Ter Arkh; 2023 Sep; 95(7):580-585. PubMed ID: 38159009
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
Villanueva B; Iriarte A; Torres-Iglesias R; Muñoz Bolaño M; Cerdà P; Riera-Mestre A
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763652
[TBL] [Abstract][Full Text] [Related]
9. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L
Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613
[TBL] [Abstract][Full Text] [Related]
10. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
Epperla N; Hocking W
Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
Kanellopoulou T; Alexopoulou A
Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
[TBL] [Abstract][Full Text] [Related]
12. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
Mitchell A; Adams LA; MacQuillan G; Tibballs J; vanden Driesen R; Delriviere L
Liver Transpl; 2008 Feb; 14(2):210-3. PubMed ID: 18236396
[TBL] [Abstract][Full Text] [Related]
14. Hereditary hemorrhagic telangiectasia/avastin.
Davidson TM; Olitsky SE; Wei JL
Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
[TBL] [Abstract][Full Text] [Related]
15. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
Arizmendez NP; Rudmik L; Poetker DM
Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
[TBL] [Abstract][Full Text] [Related]
18. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
[TBL] [Abstract][Full Text] [Related]
19. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Kim YH; Kim MJ; Choe SW; Sprecher D; Lee YJ; P Oh S
J Thromb Haemost; 2017 Jun; 15(6):1095-1102. PubMed ID: 28339142
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
